News

Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out
Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...
Why did Lilly data for oral obesity drug boost Structure and Metsera?
Obesity drug developers Structure Therapeutics (NASDAQ:GPCR) and Metsera (NASDAQ:MTSR) recorded sharp gains alongside Eli ...
Reuters11d
Novo preparing for early launch of weight-loss drug Wegovy in India
HYDERABAD, April 7 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with ...
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill
Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to ...
Why did Lilly data for oral GLP-1 boost Structure and Metsera?
Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...
Morningstar3d
Wegovy, Zepbound makers' stocks rally as a weight-loss-drug competitor drops out
That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic and Wegovy ... Agrawal said Structure Therapeutics Inc.'s aleniglipron is now the ...